Facts
Is this your organization? Claim it
By News Room
Lila Bio wins $3.65M NIH SBIR grant to develop AI-designed long‑acting injectable for pulmonary hypertension
Lila Bio, spun out of David Baker’s UW lab, won a $3.65 million NIH SBIR grant to develop an AI-designed, long-acting injectable protein therapy aimed at modifying disease in pulmonary hypertension. The funding covers two phases—$605,981 for initial animal studies and $3,049,462 for further animal work and patient lung-tissue studies—and builds on Lila’s 2023 $10M seed raise and prior collaboration with Eli Lilly.